Vor Biopharma Inc.

VOR Nasdaq SEC CIK 1817229
Follow Vor Biopharma Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$86.7M +89.3% vs same quarter last year
EPS, diluted −$1.45 +98.8% vs same quarter last year
Operating cash flow −$32.7M +39% vs same quarter last year
Operating income −$58.4M −107.9% vs same quarter last year
Net income by quarter
−$30.7M
−$32.5M
−$1.6B
−$812.7M
$1.7B
−$219.6M
−$62.8M
−$86.7M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$800M−$600M−$400M−$200M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$696M
FY24−$116.9M
FY23−$117.9M
FY22−$92.1M
FY21−$68.9M
FY20−$43.3M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$143.7M
FY24−$99.9M
FY23−$101.4M
FY22−$93.6M
FY21−$73M
FY20−$40.5M
FY19-